Revumenib As Pre-Emptive Therapy for Measurable Residual Disease in <i>NPM1</i> mutated or <i>KMT2A-</i>rearranged Acute Myeloid Leukemia: A Domain of the Multi-Arm ALLG AMLM26 Intercept Platform Trial
Sun Loo(The Royal Melbourne Hospital), Andrew H. Wei(The University of Melbourne), Harry Iland(Royal Prince Alfred Hospital), Shaun Fleming(Peter MacCallum Cancer Centre), Courtney D. DiNardo(The University of Texas MD Anderson Cancer Center), Adam Ivey(The Alfred Hospital), Anoop Enjeti(Calvary Mater Newcastle Hospital), Hannah Rose(Geelong Hospital), Ing Soo Tiong(Peter MacCallum Cancer Centre), John M. Reynolds(Alfred Health), Teng Fong Ng(Griffith University), Andrew W. Roberts(Walter and Eliza Hall Institute of Medical Research), Naval Daver(The University of Texas MD Anderson Cancer Center), Rachel Koldej(The Royal Melbourne Hospital), Chong Chyn Chua(The University of Melbourne), William Stevenson(The University of Sydney), Carolyn Grove(The University of Western Australia), Jad Othman(King's College London), Sanam Loghavi(The University of Texas MD Anderson Cancer Center), Natasha S. Anstee(Walter and Eliza Hall Institute of Medical Research), Duncan Purtill(Fiona Stanley Hospital), Deepak Singhal(Women's and Children's Health Network), Robin Gasiorowski(The University of Sydney), Paula Marlton(The University of Queensland), Lachlin Vaughan(Westmead Hospital), David Westerman(University of Melbourne), Amanda Souza(Dana-Farber Cancer Institute), McCulloch Derek(Royal Prince Alfred Hospital), Revati Pattani(Australasian Leukaemia and Lymphoma Group)
Cited by 9
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k